What would be your second line approach for a patient with MSI-H metastatic colon cancer who progressed on first line chemotherapy?

Would you switch chemotherapy regimens (i.e if the patient received FOLFOX/Avastin, change to FOLFIRI/Avastin)? Would you treat wuth immunotherapy per the latest data from Checkmate 142?

Answer from: Medical Oncologist at Academic Institution

I would definitely favor nivolumab + ipilimumab in this setting. Although we don't have a randomized comparison, the response rate, duration of response, and PFS reported in CheckMate 142 clearly exceed what we would expect with second-line chemotherapy. This is even more remarkable when you conside...

Comments

Medical Oncologist at Ralph Lauren Center for Cancer Care and Prevention
Very helpful. Thank you!

Please select the option that best describes you:

What would be your second line approach for a patient with MSI-H metastatic colon cancer who progressed on first line chemotherapy?

Related Questions